NCT06905314View on ClinicalTrials.gov

A Single Ascending Dose of HRS-4029 in Healthy Subjects

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

October 31, 2025

Study Completion Date

December 31, 2025

Conditions
Acute Ischemic Stroke
Interventions
DRUG

HRS-4029

HRS-4029

DRUG

Placebo

Placebo

Trial Locations (1)

100029

China-Japan Friendship Hospital, Beijing

All Listed Sponsors
lead

Beijing Suncadia Pharmaceuticals Co., Ltd

INDUSTRY